Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.02, read 2026-11-01
Ethical does not pass the values gate
Price26.50 USD
Fair value24.75
Ethical score10.0/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-11-05Read Markup26.50+0.0% to today ✓Accumulation gives way to Markup after a 9% rise in 3 weeks
2026-10-13Read Accumulation24.35+8.8% to today ✓Markdown gives way to Accumulation with results news in the headlines
2026-10-02Read Markdown23.48+12.9% to today Markup gives way to Markdown after a 21% rise in 13 weeks
2026-07-02Read Markup19.38+36.7% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Baxter International holds its Markup at $26.50. The statistical read favours the buyers, held for 1 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 1 days
Price at the screen
$26.50
Valuation
N/A trailing · 12.48 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.67
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
48.77%
Below 33%
Interest-bearing debt is 48.8% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.51%
Below 33%
Cash held in interest-bearing accounts and securities is 0.5% of assets, under the one-third limit.
Pass
Receivables
19.08%
Below 49%
Money owed to the company is 19.1% of assets, under the 49% limit.
Pass
Revenue purity
0.46%
Below 5%
Only 0.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Baxter International's business is in a permissible area, but its interest-bearing debt is about 49% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BAX's ethical verdict changes
Today BAX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 4 Nov 2026: it trades above our $24.75 fair value estimate, weak competitive moat, 5.00% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 7.1% above the base estimate.
Where our models see it going: fair-value estimate $24.75, with a range of $18.00 to $29.36, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Medical supplier weighed down by heavy debt
Hospitals depend on steady flows of sterile bags and therapies, yet Baxter keeps borrowing more than its operations can comfortably carry. We pass because the ethical screen rejects the debt load outright, and the business shows no sign of the growth or returns needed to justify the price above our fair value.
Forward earnings sit at 11.3 times while revenue edges up just 3 percent and both profit margin and return on equity sit deep in negative territory. A weak moat leaves it exposed to competitors that move faster on innovation and pricing.
Analysts sit on hold with targets near current levels, but the real concern remains leverage that could tighten further if healthcare spending slows. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BAX trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup · changed$26.50+4.1%Entry 17
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 35%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it hold, with a mean price target of $22. Since the last review it its composite score eased.
2026-10-29Accumulation$25.46+1.9%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 35%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it hold, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$24.99+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 35%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it hold, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$24.99+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 35%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it hold, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$24.99+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 35%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it hold, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$24.99+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 35%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it hold, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$24.99+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 35%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it hold, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$24.99+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 35%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it hold, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$24.99+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 35%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it hold, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Accumulation$24.99+2.6%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 35%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it hold, with a mean price target of $22.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.